Finally, we got the opportunity to speak with Antony about today company update and ask a few questions we hope shareholders find informative. What is cleary stated, P2F’s company portfolio
The Company is pleased to report the significant progress achieved since the announcement on 18 February.
New clinical guidance in the UK supports assay
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Further to the announcements on 29 January 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
The U.S. government on Saturday authorized Johnson & Johnson’s (JNJ.N) single-dose COVID-19 vaccine, enabling millions more Americans to be vaccinated in the coming weeks and setting it up for additional
U.S. regulators on Friday said they would work quickly to authorize Johnson & Johnson’s COVID-19 vaccine for emergency use after a panel of outside advisers backed the one-shot immunization.
Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report
AffiDX®, SARS-CoV-2 Lateral Flow Rapid Antigen Test generates excellent initial clinical sensitivity and specificity data MHRA approves Clinical Trial Authorisation of first therapeutic product candidate
Lateral flow test data shows potential for companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, notes the recent press speculation about UK Government take-up of Avacta’s lateral flow SARS-CoV-2 rapid antigen test.
